<?xml version='1.0' encoding='utf-8'?>
<document id="22282958"><sentence text="Drug-drug interaction study between a novel oral ibandronate formulation and metformin."><entity charOffset="49-60" id="DDI-PubMed.22282958.s1.e0" text="ibandronate" /><entity charOffset="77-86" id="DDI-PubMed.22282958.s1.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.22282958.s1.e0" e2="DDI-PubMed.22282958.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22282958.s1.e0" e2="DDI-PubMed.22282958.s1.e1" /></sentence><sentence text="The novel excipient, sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC, CAS 203787-91-1) increases the oral bioavailability of co-formulated ibandronate (IBN, CAS 138926-19)"><entity charOffset="21-66" id="DDI-PubMed.22282958.s2.e0" text="sodium N-[8-(2-hydroxybenzoyl)amino]caprylate" /><entity charOffset="68-72" id="DDI-PubMed.22282958.s2.e1" text="SNAC" /><entity charOffset="143-154" id="DDI-PubMed.22282958.s2.e2" text="ibandronate" /><entity charOffset="156-159" id="DDI-PubMed.22282958.s2.e3" text="IBN" /><pair ddi="false" e1="DDI-PubMed.22282958.s2.e0" e2="DDI-PubMed.22282958.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22282958.s2.e0" e2="DDI-PubMed.22282958.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22282958.s2.e0" e2="DDI-PubMed.22282958.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22282958.s2.e0" e2="DDI-PubMed.22282958.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22282958.s2.e1" e2="DDI-PubMed.22282958.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22282958.s2.e1" e2="DDI-PubMed.22282958.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22282958.s2.e1" e2="DDI-PubMed.22282958.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22282958.s2.e2" e2="DDI-PubMed.22282958.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22282958.s2.e2" e2="DDI-PubMed.22282958.s2.e3" /></sentence><sentence text=" The aim of this study was to investigate the effect of the IBN/SNAC formulation on the steady-state pharmacokinetics of metformin (CAS 657-24-9) and to assess safety and tolerability of IBN/SNAC when dosed in combination with metformin"><entity charOffset="121-130" id="DDI-PubMed.22282958.s3.e0" text="metformin" /><entity charOffset="227-236" id="DDI-PubMed.22282958.s3.e1" text="metformin" /><entity charOffset="64-72" id="DDI-PubMed.22282958.s3.e2" text="SNAC" /><entity charOffset="191-199" id="DDI-PubMed.22282958.s3.e3" text="SNAC" /><entity charOffset="60-68" id="DDI-PubMed.22282958.s3.e4" text="IBN" /><entity charOffset="187-195" id="DDI-PubMed.22282958.s3.e5" text="IBN" /><pair ddi="false" e1="DDI-PubMed.22282958.s3.e4" e2="DDI-PubMed.22282958.s3.e4" /><pair ddi="false" e1="DDI-PubMed.22282958.s3.e4" e2="DDI-PubMed.22282958.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22282958.s3.e4" e2="DDI-PubMed.22282958.s3.e0" /><pair ddi="false" e1="DDI-PubMed.22282958.s3.e4" e2="DDI-PubMed.22282958.s3.e5" /><pair ddi="false" e1="DDI-PubMed.22282958.s3.e4" e2="DDI-PubMed.22282958.s3.e3" /><pair ddi="false" e1="DDI-PubMed.22282958.s3.e4" e2="DDI-PubMed.22282958.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22282958.s3.e2" e2="DDI-PubMed.22282958.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22282958.s3.e2" e2="DDI-PubMed.22282958.s3.e0" /><pair ddi="false" e1="DDI-PubMed.22282958.s3.e2" e2="DDI-PubMed.22282958.s3.e5" /><pair ddi="false" e1="DDI-PubMed.22282958.s3.e2" e2="DDI-PubMed.22282958.s3.e3" /><pair ddi="false" e1="DDI-PubMed.22282958.s3.e2" e2="DDI-PubMed.22282958.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22282958.s3.e0" e2="DDI-PubMed.22282958.s3.e0" /><pair ddi="false" e1="DDI-PubMed.22282958.s3.e0" e2="DDI-PubMed.22282958.s3.e5" /><pair ddi="false" e1="DDI-PubMed.22282958.s3.e0" e2="DDI-PubMed.22282958.s3.e3" /><pair ddi="false" e1="DDI-PubMed.22282958.s3.e0" e2="DDI-PubMed.22282958.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22282958.s3.e5" e2="DDI-PubMed.22282958.s3.e5" /><pair ddi="false" e1="DDI-PubMed.22282958.s3.e5" e2="DDI-PubMed.22282958.s3.e3" /><pair ddi="false" e1="DDI-PubMed.22282958.s3.e5" e2="DDI-PubMed.22282958.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22282958.s3.e3" e2="DDI-PubMed.22282958.s3.e3" /><pair ddi="false" e1="DDI-PubMed.22282958.s3.e3" e2="DDI-PubMed.22282958.s3.e1" /></sentence><sentence text=" Twenty-two healthy subjects received metformin on Days 1 to 6"><entity charOffset="38-47" id="DDI-PubMed.22282958.s4.e0" text="metformin" /></sentence><sentence text=" On Day 7, subjects received metformin together with the IBN/ SNAC formulation"><entity charOffset="29-38" id="DDI-PubMed.22282958.s5.e0" text="metformin" /><entity charOffset="62-70" id="DDI-PubMed.22282958.s5.e1" text="SNAC" /><entity charOffset="57-65" id="DDI-PubMed.22282958.s5.e2" text="IBN" /><pair ddi="false" e1="DDI-PubMed.22282958.s5.e0" e2="DDI-PubMed.22282958.s5.e0" /><pair ddi="false" e1="DDI-PubMed.22282958.s5.e0" e2="DDI-PubMed.22282958.s5.e2" /><pair ddi="false" e1="DDI-PubMed.22282958.s5.e0" e2="DDI-PubMed.22282958.s5.e1" /><pair ddi="false" e1="DDI-PubMed.22282958.s5.e2" e2="DDI-PubMed.22282958.s5.e2" /><pair ddi="false" e1="DDI-PubMed.22282958.s5.e2" e2="DDI-PubMed.22282958.s5.e1" /></sentence><sentence text=" The safety and tolerability of IBN/SNAC co-administered with metformin was consistent with the known safety profile of the single medications"><entity charOffset="62-71" id="DDI-PubMed.22282958.s6.e0" text="metformin" /><entity charOffset="36-44" id="DDI-PubMed.22282958.s6.e1" text="SNAC" /><entity charOffset="32-40" id="DDI-PubMed.22282958.s6.e2" text="IBN" /><pair ddi="false" e1="DDI-PubMed.22282958.s6.e2" e2="DDI-PubMed.22282958.s6.e2" /><pair ddi="false" e1="DDI-PubMed.22282958.s6.e2" e2="DDI-PubMed.22282958.s6.e1" /><pair ddi="false" e1="DDI-PubMed.22282958.s6.e2" e2="DDI-PubMed.22282958.s6.e0" /><pair ddi="false" e1="DDI-PubMed.22282958.s6.e1" e2="DDI-PubMed.22282958.s6.e1" /><pair ddi="false" e1="DDI-PubMed.22282958.s6.e1" e2="DDI-PubMed.22282958.s6.e0" /></sentence><sentence text=" The increase in mean maximum plasma concentration (Cmax) and mean overall exposure to metformin (AUC0-tau,) was approximately 7%"><entity charOffset="87-96" id="DDI-PubMed.22282958.s7.e0" text="metformin" /></sentence><sentence text=" The entire 90% confidence intervals for the AUC- and Cmax-ratios did fall within the acceptance region for bioequivalence (0" /><sentence text="8-1" /><sentence text="25)" /><sentence text=" In summary, administration of the IBN/ SNAC formulation together with metformin did not lead to a significant increase in exposure to metformin"><entity charOffset="71-80" id="DDI-PubMed.22282958.s11.e0" text="metformin" /><entity charOffset="135-144" id="DDI-PubMed.22282958.s11.e1" text="metformin" /><entity charOffset="40-48" id="DDI-PubMed.22282958.s11.e2" text="SNAC" /><entity charOffset="35-43" id="DDI-PubMed.22282958.s11.e3" text="IBN" /><pair ddi="false" e1="DDI-PubMed.22282958.s11.e3" e2="DDI-PubMed.22282958.s11.e3" /><pair ddi="false" e1="DDI-PubMed.22282958.s11.e3" e2="DDI-PubMed.22282958.s11.e2" /><pair ddi="false" e1="DDI-PubMed.22282958.s11.e3" e2="DDI-PubMed.22282958.s11.e0" /><pair ddi="false" e1="DDI-PubMed.22282958.s11.e3" e2="DDI-PubMed.22282958.s11.e1" /><pair ddi="false" e1="DDI-PubMed.22282958.s11.e2" e2="DDI-PubMed.22282958.s11.e2" /><pair ddi="false" e1="DDI-PubMed.22282958.s11.e2" e2="DDI-PubMed.22282958.s11.e0" /><pair ddi="false" e1="DDI-PubMed.22282958.s11.e2" e2="DDI-PubMed.22282958.s11.e1" /><pair ddi="false" e1="DDI-PubMed.22282958.s11.e0" e2="DDI-PubMed.22282958.s11.e0" /><pair ddi="false" e1="DDI-PubMed.22282958.s11.e0" e2="DDI-PubMed.22282958.s11.e1" /></sentence><sentence text=" The study medication was well tolerated in healthy volunteers" /><sentence text="" /></document>